For Immediate Release
Chicago, IL - June 02, 2016 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Sarepta ( SRPT ), Biogen ( BIIB ), AbbVie ( ABBV ), Intercept ( ICPT ) and Ionis ( IONS ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Wednesday's Analyst Blog:
Biotech Stock Roundup
This week, the biotech sector saw quite a few updates on the regulatory and pipeline front. While companies like Sarepta ( SRPT ), Biogen ( BIIB ), AbbVie ( ABBV ) and Intercept ( ICPT ) came out with encouraging news, Ionis ( IONS ) suffered a setback.
Recap of the Week's Most Important Stories
1. Sarepta's shares shot up 26.7% on news that the FDA will not be able to deliver a decision regarding the approval status of the company's experimental Duchenne muscular dystrophy (DMD) treatment, eteplirsen, by May 26. The agency informed the company that it continues to review the NDA and will return with a decision in a timely manner. The news has raised hopes among investors as well as the medical community that the agency may very well decide to approve eteplirsen (Read more: Why is Sarepta Therapeutics Stock Soaring 20% Today? ).
We remind investors that DMD drugs have not really had much success on the regulatory front so far. While PTC Therapeutics had received a "refusal to file" letter from the FDA for its experimental DMD treatment, Translarna, BioMarin's Kyndrisa received a complete response letter (CRL) earlier this year. BioMarin, in fact, announced this week that it does not intend to continue with the development of Kyndrisa. The company withdrew its marketing application in the EU following discussions with the Committee for Medicinal Products for Human Use (CHMP) which indicated the drug would receive a negative opinion from the CHMP.
2. Across the pond, quite a few drugs received positive CHMP opinions including Biogen's Tysabri (label expansion for use in relapsing-remitting multiple sclerosis patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy) as well as Gilead's experimental hepatitis C virus (HCV) drug, Epclusa (Read more: Gilead's New HCV Drug Epclusa Wins CHMP Backing ). Amgen's cancer drug Kyprolis and AbbVie's flagship product Humira also got positive CHMP opinions for label expansions (Read more: Merck, AbbVie & Amgen Drugs a Step Closer to EU Approval ).
3. The FDA granted approval to Biogen and AbbVie's multiple sclerosis (MS) treatment Zinbryta making it the first once-monthly, self-administered MS treatment to be approved. However, the label has a black box warning regarding the risk of hepatic injury, including autoimmune hepatitis, and other immune-mediated disorders. Moreover, only prescribers, pharmacies and patients enrolled in the Zinbryta Risk Evaluation and Mitigation Strategy (REMS) Program, which includes required monthly liver function tests, will have access to the treatment. (Read more: Biogen & AbbVie's Multiple Sclerosis Drug Gets FDA Nod ).
AbbVie's cancer treatment, Imbruvica, also gained EU approval for the first-line treatment of chronic lymphocytic leukemia (CLL) patients. The label expansion was expected as the CHMP had recently issued a positive opinion for this indication. With this label expansion, Imbruvica can now be used across all lines of CLL.
4. Ionis' shares were down 39.4% on news that Glaxo, which has the option to exclusively license Ionis' IONIS-TTRRx, has decided against initiating a phase III outcome study in patients with TTR amyloid cardiomyopathy. The study had been placed on clinical hold earlier this year due to safety findings in the ongoing NEURO-TTR study. (Read more: Ionis Down, Glaxo Dumps IONIS-TTRRx Phase III Study Plans ).
5. Intercept's Ocaliva gained accelerated approval in the U.S. for the treatment of primary biliary cholangitis (PBC) making it the first new medicine to be approved for PBC in almost two decades. Shares were up on the news though approval was largely expected as an FDA advisory panel had voted unanimously in favor of approving the drug. (Read more: Intercept's Liver Dug Ocaliva Approved by the FDA ). Of course, Ocaliva's main potential lies in the nonalcoholic steatohepatitis (NASH) market which represents blockbuster potential.
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today .
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros .
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SAREPTA THERAP (SRPT): Free Stock Analysis Report
BIOGEN INC (BIIB): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
INTERCEPT PHARM (ICPT): Free Stock Analysis Report
IONIS PHARMACT (IONS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
